Replimune Group, Inc. (REPL)Healthcare | Biotechnology | Woburn, United States | NasdaqGS
9.94 USD
-1.06
(-9.600%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 9.80 -0.14 (-0.135%) ⇩ (July 13, 2026, 7:41 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 4:38 a.m. EDT
The investment case for Replimune is currently paralyzed by the binary nature of its FDA decision on its melanoma drug. Fundamentally, the company is in distress: it is burning significant cash with negative free cash flow and negative returns on equity, and the stock has suffered a severe multi-year decline, dropping nearly 53% in the last year alone. This trajectory suggests the market has already priced in a failure of the drug or a lack of commercial viability, leaving the balance sheet fragile. While the recent price action shows some resilience and a slight uptick in the trailing twelve months, the underlying business metrics remain deeply concerning with no path to profitability visible. The options market confirms this tension, with heavy betting on both a catastrophic drop and a miraculous approval, but the lack of a reliable catalyst beyond the FDA vote makes the risk-reward profile unattractive for a standard investor. Without a confirmed approval and a clear plan to generate revenue, the stock remains a speculative gamble on a binary event rather than a sound investment. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.886439 |
| AutoETS | 0.928547 |
| AutoARIMA | 0.930122 |
| AutoTheta | 0.949323 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 25% |
| H-stat | 10.66 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.156 |
| Excess Kurtosis | -1.05 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 67.156 |
| Market Cap | 833,995,200 |
| Forward P/E | -8.61 |
| Beta | 0.87 |
| Website | https://www.replimune.com |
As of July 11, 2026, 4:38 a.m. EDT: Speculators are positioning aggressively for volatility rather than a specific directional outcome. There is a massive concentration of out-of-the-money put open interest at strikes significantly below the current price (e.g., $2, $5, $6), indicating a 'crash' hedge or a bet on regulatory rejection driving the stock lower. Conversely, there is also heavy call open interest at distant strikes ($17, $20), suggesting a binary bet on a successful FDA approval causing a sharp spike. The implied volatility is elevated across the board, reflecting uncertainty surrounding the upcoming FDA decision. The options flow suggests a polarized view where traders are hedging against a downside event while simultaneously buying deep out-of-the-money calls to capture a potential upside surprise.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.025709212 |
| Address1 | 500 Unicorn Park Drive |
| Address2 | Suite 303, 3rd Floor |
| All Time High | 54.85 |
| All Time Low | 1.5 |
| Ask | 12.58 |
| Ask Size | 2 |
| Audit Risk | 10 |
| Average Analyst Rating | 2.9 - Hold |
| Average Daily Volume10 Day | 3,591,940 |
| Average Daily Volume3 Month | 6,668,924 |
| Average Volume | 6,668,924 |
| Average Volume10Days | 3,591,940 |
| Beta | 0.868 |
| Bid | 7.78 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 2.009 |
| City | Woburn |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 6 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 9.935 |
| Current Ratio | 4.794 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 10.91 |
| Day Low | 9.79 |
| Debt To Equity | 67.156 |
| Display Name | Replimune |
| Earnings Call Timestamp End | 1,747,915,200 |
| Earnings Call Timestamp Start | 1,747,915,200 |
| Earnings Timestamp | 1,782,736,200 |
| Earnings Timestamp End | 1,786,019,400 |
| Earnings Timestamp Start | 1,786,019,400 |
| Ebitda | -312,555,008 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.165 |
| Enterprise Value | 676,692,160 |
| Eps Current Year | -1.935 |
| Eps Forward | -1.15333 |
| Eps Trailing Twelve Months | -3.38 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 7.647 |
| Fifty Day Average Change | 2.2880006 |
| Fifty Day Average Change Percent | 0.29920238 |
| Fifty Two Week Change Percent | -2.5709212 |
| Fifty Two Week High | 13.24 |
| Fifty Two Week High Change | -3.3049994 |
| Fifty Two Week High Change Percent | -0.24962232 |
| Fifty Two Week Low | 1.5 |
| Fifty Two Week Low Change | 8.435 |
| Fifty Two Week Low Change Percent | 5.6233335 |
| Fifty Two Week Range | 1.5 - 13.24 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,532,093,400,000 |
| Float Shares | 59,711,872 |
| Forward Eps | -1.15333 |
| Forward P E | -8.614187 |
| Free Cashflow | -172,249,744 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 465 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0256 |
| Held Percent Institutions | 0.95449996 |
| Implied Shares Outstanding | 83,945,161 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,774,915,200 |
| Long Business Summary | Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4. The company was founded in 2015 and is headquartered in Woburn, Massachusetts. |
| Long Name | Replimune Group, Inc. |
| Market | us_market |
| Market Cap | 833,995,200 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_571664452 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -313,940,000 |
| Next Fiscal Year End | 1,806,451,200 |
| Non Diluted Market Cap | 922,977,045 |
| Number Of Analyst Opinions | 6 |
| Open | 10.9 |
| Operating Cashflow | -280,344,000 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 781 222 9600 |
| Post Market Change | -0.13500023 |
| Post Market Change Percent | -1.3588346 |
| Post Market Price | 9.8 |
| Post Market Time | 1,783,986,076 |
| Previous Close | 10.99 |
| Price Eps Current Year | -5.1343675 |
| Price Hint | 2 |
| Price To Book | 4.945246 |
| Profit Margins | 0.0 |
| Quick Ratio | 4.646 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | hold |
| Recommendation Mean | 2.875 |
| Region | US |
| Regular Market Change | -1.055 |
| Regular Market Change Percent | -9.59963 |
| Regular Market Day High | 10.91 |
| Regular Market Day Low | 9.79 |
| Regular Market Day Range | 9.79 - 10.91 |
| Regular Market Open | 10.9 |
| Regular Market Previous Close | 10.99 |
| Regular Market Price | 9.935 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 2,828,130 |
| Return On Assets | -0.45025003 |
| Return On Equity | -1.07883 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 83,945,161 |
| Shares Percent Shares Out | 0.28190002 |
| Shares Short | 23,666,879 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 25,954,343 |
| Short Name | Replimune Group, Inc. |
| Short Percent Of Float | 0.4988 |
| Short Ratio | 5.48 |
| Source Interval | 15 |
| State | MA |
| Symbol | REPL |
| Target High Price | 17.0 |
| Target Low Price | 2.0 |
| Target Mean Price | 10.66667 |
| Target Median Price | 10.0 |
| Total Cash | 268,888,992 |
| Total Cash Per Share | 3.203 |
| Total Debt | 111,586,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.38 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 7.4691 |
| Two Hundred Day Average Change | 2.4659004 |
| Two Hundred Day Average Change Percent | 0.33014694 |
| Type Disp | Equity |
| Volume | 2,828,130 |
| Website | https://www.replimune.com |
| Zip | 1,801 |